Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.63 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19195276 | 0.96 | CNR1 (0.61) | EPHX2CNR1 | |
| SCHEMBL13561441 | 0.96 | CNR1 (0.61) | EPHX2CNR1 | |
| SCHEMBL12148860 | 0.91 | EPHX2 (0.66) | EPHX2SLC6A5 | |
| SCHEMBL13339080 | 0.91 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12148864 | 0.91 | EPHX2 (0.60) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12148863 | 0.91 | EPHX2 (0.60) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12087756 | 0.91 | EPHX2 (0.60) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL1869135 | 0.91 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL13339079 | 0.91 | EPHX2 (0.66) | EPHX2SLC6A5 | |
| SCHEMBL1869136 | 0.91 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160338957-A1 | IMINO COMPOUNDS FOR AMPHOTERIC LIPOSOMES AND USES THEREOF | BIONTECH PROTEIN THERAPEUTICS GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20120237589-A1 | AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS | MARINA BIOTECH, INC. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338957-A1 | IMINO COMPOUNDS FOR AMPHOTERIC LIPOSOMES AND USES THEREOF | IPO8, IPO7, PHOSPHO1 | EPHX2 2834/4885SLC6A5 2101/4885LPAR3 117/4885 |
| US-20120237589-A1 | AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS | SGMS1, SGMS2, PHOSPHO1 | EPHX2 2882/4885SLC6A5 2711/4885LPAR3 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.